Rein Therapeutics (NASDAQ:RNTX) Given Hold Rating at Brookline Capital Management

Brookline Capital Management reaffirmed their hold rating on shares of Rein Therapeutics (NASDAQ:RNTX) in a research note released on Tuesday,Benzinga reports.

Rein Therapeutics Price Performance

Rein Therapeutics stock opened at $1.10 on Tuesday. Rein Therapeutics has a 12-month low of $1.04 and a 12-month high of $4.40. The stock has a market cap of $25.36 million, a P/E ratio of -0.41 and a beta of 1.31. The business’s fifty day moving average price is $1.42.

Rein Therapeutics (NASDAQ:RNTX) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.06). As a group, sell-side analysts predict that Rein Therapeutics will post -1.56 earnings per share for the current year.

Institutional Investors Weigh In On Rein Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. BIOS Capital Management LP acquired a new position in shares of Rein Therapeutics in the second quarter valued at approximately $2,367,000. Voss Capital LP bought a new position in shares of Rein Therapeutics in the second quarter valued at about $2,007,000. University of Texas Texas AM Investment Management Co. acquired a new stake in Rein Therapeutics during the second quarter worth about $716,000. Cable Car Capital LP acquired a new stake in shares of Rein Therapeutics in the 2nd quarter valued at approximately $588,000. Finally, Sigma Planning Corp bought a new position in Rein Therapeutics in the 2nd quarter valued at approximately $387,000. 90.89% of the stock is owned by institutional investors.

About Rein Therapeutics

Rein Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers.